免疫治疗超进展的研究进展

doi:10.3760/cma.j.cn371439-20200118-00111

摘要/Abstract

摘要：

超进展是肿瘤患者在以程序性死亡蛋白-1及其配体(PD-1/PD-L1)抑制剂为代表的免疫治疗中出现的一种新的进展模式,其表现为在抗PD-1/PD-L1免疫治疗后,患者情况恶化,肿瘤加快生长。目前因为其机制尚不明朗及缺少有效的治疗方法,超进展的发生率较高,患者预后较差。

关键词: 免疫疗法, 超进展, PD-1/PD-L1

Abstract:

Hyperprogressive disease is a new pattern of progression recently described in patients with cancer treated with immunotherapeutics, which are represented by programmed cell death-1 and programmed cell death ligand-1 (PD-1/PD-L1) inhibitors. Hyperprogressive manifests as after anti-PD-1/PD-L1 immunotherapy, the patient's condition worsens and tumor grows faster. At present, on account of its unclear mechanism and a lack of effective treatment methods, the incidence of hyperprogressive is high and the prognosis of hyperprogressive patients is poor.

Key words: Immunotherapy, Hyperprogression, PD-1/PD-L1

徐阳涛, 陈彪, 何晓琴, 徐细明. 免疫治疗超进展的研究进展[J]. 国际肿瘤学杂志, 2020, 47(12): 737-740.

Xu Yangtao, Chen Biao, He Xiaoqin, Xu Ximing. Research progress of hyperprogressive disease after immunotherapy[J]. Journal of International Oncology, 2020, 47(12): 737-740.

参考文献 28

[1]	Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer[J]. N Engl J Med, 2012,366(26):2443-2454. DOI: 10.1056/NEJMoa1200690. doi: 10.1056/NEJMoa1200690 pmid: 22658127
[2]	Robert C, Long GV, Brady B, et al. Nivolumab in previously untrea-ted melanoma without BRAF mutation[J]. N Engl J Med, 2015,372(4):320-330. DOI: 10.1056/NEJMoa1412082. doi: 10.1056/NEJMoa1412082 pmid: 25399552
[3]	Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer[J]. N Engl J Med, 2015,373(17):1627-1639. DOI: 10.1056/NEJMoa1507643. doi: 10.1056/NEJMoa1507643 pmid: 26412456
[4]	Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer[J]. N Engl J Med, 2015,373(2):123-135. DOI: 10.1056/NEJMoa1504627. doi: 10.1056/NEJMoa1504627 pmid: 26028407
[5]	Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial[J]. Lancet, 2016,387(10027):1540-1550. DOI: 10.1016/s0140-6736(15)01281-7. doi: 10.1016/S0140-6736(15)01281-7 pmid: 26712084
[6]	Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma[J]. N Engl J Med, 2015,373(19):1803-1813. DOI: 10.1056/NEJMoa1510665. doi: 10.1056/NEJMoa1510665 pmid: 26406148
[7]	Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck[J]. N Engl J Med, 2016,375(19):1856-1867. DOI: 10.1056/NEJMoa1602252. doi: 10.1056/NEJMoa1602252 pmid: 27718784
[8]	Sharon E. Can an immune checkpoint inhibitor (sometimes) make things worse?[J]. Clin Cancer Res, 2017,23(8):1879-1881. DOI: 10.1158/1078-0432.CCR-16-2926. doi: 10.1158/1078-0432.CCR-16-2926 pmid: 28258060
[9]	Chubachi S, Yasuda H, Irie H, et al. A case of non-small cell lung cancer with possible "disease flare" on nivolumab treatment[J]. Case Rep Oncol Med, 2016,2016:1075641. DOI: 10.1155/2016/1075641. doi: 10.1155/2016/1075641 pmid: 28116195
[10]	Yoshida T, Furuta H, Hida T. Risk of tumor flare after nivolumab treatment in patients with irradiated field recurrence[J]. Med Oncol, 2017,34(3):34. DOI: 10.1007/s12032-017-0895-4. doi: 10.1007/s12032-017-0895-4 pmid: 28138869
[11]	Champiat S, Dercle L, Ammari S, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1[J]. Clin Cancer Res, 2017,23(8):1920-1928. DOI: 10.1158/1078-0432.CCR-16-1741. doi: 10.1158/1078-0432.CCR-16-1741 pmid: 27827313
[12]	Saada-Bouzid E, Defaucheux C, Karabajakian A, et al. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma[J]. Ann Oncol, 2017,28(7):1605-1611. DOI: 10.1093/annonc/mdx178. doi: 10.1093/annonc/mdx178 pmid: 28419181
[13]	Kato S, Goodman A, Walavalkar V, et al. Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate[J]. Clin Cancer Res, 2017,23(15):4242-4250. DOI: 10.1158/1078-0432.CCR-16-3133. doi: 10.1158/1078-0432.CCR-16-3133 pmid: 28351930
[14]	Ferrara R, Mezquita L, Texier M, et al. Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy[J]. JAMA Oncol, 2018,4(11):1543-1552. DOI: 10.1001/jamaoncol.2018.3676. doi: 10.1001/jamaoncol.2018.3676 pmid: 30193240
[15]	Weiss GJ, Beck J, Braun DP, et al. Tumor cell-free DNA copy number instability predicts therapeutic response to immunotherapy[J]. Clin Cancer Res, 2017,23(17):5074-5081. DOI: 10.1158/1078-0432.CCR-17-0231. doi: 10.1158/1078-0432.CCR-17-0231 pmid: 28320758
[16]	Lahmar J, Mezquita L, Koscielny S, et al. Immune checkpoint inhibitors ( IC) induce paradoxical progression in a subset of non-small cell lung cancer ( NSCLC) [J]. Ann Oncol, 2016, 27 Suppl 6: vi423. DOI: 10.1093/annonc/mdw383.22.
[17]	Kanjanapan Y, Day D, Wang L, et al. Hyperprogressive disease in early-phase immunotherapy trials: clinical predictors and association with immune-related toxicities[J]. Cancer, 2019,125(8):1341-1349. DOI: 10.1002/cncr.31999. doi: 10.1002/cncr.31999 pmid: 30768786
[18]	Lo Russo G, Moro M, Sommariva M, et al. Antibody-Fc/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer subsequent to PD-1/PD-L1 blockade[J]. Clin Cancer Res, 2019,25(3):989-999. DOI: 10.1158/1078-0432.CCR-18-1390. doi: 10.1158/1078-0432.CCR-18-1390 pmid: 30206165
[19]	Kim CG, Kim KH, Pyo KH, et al. Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer[J]. Ann Oncol, 2019,30(7):1104-1113. DOI: 10.1093/annonc/mdz123. doi: 10.1093/annonc/mdz123 pmid: 30977778
[20]	Sharma P, Hu-Lieskovan S, Wargo JA, et al. Primary, adaptive, and acquired resistance to cancer immunotherapy[J]. Cell, 2017,168(4):707-723. DOI: 10.1016/j.cell.2017.01.017. doi: 10.1016/j.cell.2017.01.017 pmid: 28187290
[21]	Lee CK, Man J, Lord S, et al. Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer-a meta-analysis[J]. J Thorac Oncol, 2017,12(2):403-407. DOI: 10.1016/j.jtho.2016.10.007. doi: 10.1016/j.jtho.2016.10.007 pmid: 27765535
[22]	Solana R, Tarazona R, Gayoso I, et al. Innate immunosenescence: effect of aging on cells and receptors of the innate immune system in humans[J]. Semin Immunol, 2012,24(5):331-341. DOI: 10.1016/j.smim.2012.04.008. doi: 10.1016/j.smim.2012.04.008 pmid: 22560929
[23]	Gainor JF, Shaw AT, Sequist LV, et al. EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis[J]. Clin Cancer Res, 2016,22(18):4585-4593. DOI: 10.1158/1078-0432.Ccr-15-3101. doi: 10.1158/1078-0432.CCR-15-3101 pmid: 27225694
[24]	Ferretti GR, Giaj Levra M, Jankowski A, et al. Hyperprogressive disease of non-small-cell lung adenocarcinoma under immune-checkpoint inhibitors: a new response pattern to be recognized by the radiologist[J]. Diagn Interv Imaging, 2019,100(5):313-315. DOI: 10.1016/j.diii.2018.12.004. doi: 10.1016/j.diii.2018.12.004 pmid: 30745041
[25]	Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors[J]. J Clin Oncol, 2015,33(31):3541-3543. DOI: 10.1200/jco.2015.61.6870. doi: 10.1200/JCO.2015.61.6870 pmid: 26261262
[26]	Kurman JS, Murgu SD. Hyperprogressive disease in patients with non-small cell lung cancer on immunotherapy[J]. J Thorac Dis, 2018,10(2):1124-1128. DOI: 10.21037/jtd.2018.01.79. doi: 10.21037/jtd.2018.01.79 pmid: 29607190
[27]	Chae YK, Wang S, Nimeiri H, et al. Pseudoprogression in micro-satellite instability-high colorectal cancer during treatment with combination T cell mediated immunotherapy: a case report and literature review[J]. Oncotarget, 2017,8(34):57889-57897. DOI: 10.18632/oncotarget.18361. doi: 10.18632/oncotarget.18361 pmid: 28915720
[28]	Hodi FS, Hwu WJ, Kefford R, et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab[J]. J Clin Oncol, 2016,34(13):1510-1517. DOI: 10.1200/JCO.2015.64.0391. doi: 10.1200/JCO.2015.64.0391 pmid: 26951310